CytoMed Therapeutics Limited
GDTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -82.1% | – | -100% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100.7% | 131.4% | – | 96.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,443% | -1,011.1% | – | -1,244.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,621.1% | -1,077.8% | – | -1,822.3% |
| EPS Diluted | -0.16 | -0.29 | -0.3 | -0.22 |
| % Growth | 44.8% | 3.3% | -36.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |